Pages

Showing posts with label Therapy. Show all posts
Showing posts with label Therapy. Show all posts

Tuesday, December 2, 2014

Therapy for Suffer From Tinnitus

Do you suffer with ringing, buzzing or hissing noises in your ears? If so, you’ve probably been diagnosed with Tinnitus. Even if you don’t have an official diagnosis, you know what suffering is like. You probably find it difficult to sleep and function normally – especially when the Tinnitus is at it’s worst.

The greatest thing is that this information can help you the way drugs can never help you. You can find relief without walking around in a haze all the time or feeling as if your entire life is a blur because of medication.Read more...
 

Thursday, November 27, 2014

Brand New High-converting Health Product With Strong Deep Funnel

If you’re watching this exclusive presentation, then you’re either one of my elite subscribers, or I have allowed a very close friend of mine to share this website with you.

In the next few minutes, I’m going to share with you a simple but powerful technique that's going to help you get natural clear vision.You definitely want to turn up the volume if you’re interested in...

  • Saying Goodbye to ever wearing glasses again
  • Eleminating the need to pay expensive fees for contact lenses
  • Never fearing going blind as you age
  • Never being afraid of having to undertake corrective eye surgery like LASIK

Now before we go any further, let me remind you that this is an exclusive, by invitation only presentation. You won't find this presentation anywhere else. If you're suffering from...


-> Eye Strain
-> Dyslexia
-> Cataract
-> Glaucoma
-> Poor night vision
-> Astigmatism
-> Near-Sightedness
-> Far-Sightedness
-> Old Age Sight 
-> Macular Degeneration

Bottom line is, if you've got anything less than perfect 20/20 vision, Read More…

Monday, April 2, 2012

Advances in melanoma therapy

The increasing incidence of melanoma and ever younger age of the patients determined the world of science to find effective drugs. Some are already on the market, others are under investigation.


- Each year in Europe, there has been a 68 thousand. new cases of metastatic melanoma, more than 20 thousand. patients die. It is barely 4 percent. incidence among all skin cancers, but accounts for 80 percent. deaths - said Axel Hoose, responsible for the department of immunology and oncology, Bristol Myers Squibb Company, at a press conference organized as part of this year's European Oncology Multidisciplinary Congress in Stockholm (23-27 September 2011.). 


Cancer 
 youth
In countries such as Great Britain takes on epidemic proportions. Drastically reduces the average age of the patients. Melanoma is the most common cancer among 20th years old. In Poland, for the time being in the second ten most common cancers.

- This shows the difference in the determination to fight the disease - summarizes the epidemiology of cancer Piotr Rutkowski, director of Cancer Soft Tissue Clinic, Bone and Czerniaków Free Society:

- Just look at the growing number of sessions devoted to this type of cancer in the international oncology meetings. 
 
 The metastatic melanoma has come to be loud at last year's ASCO information due to the progress in this area has not been seen since the 70s these.


Long-term survival
In 2010, the magazine published the NEJM study ipilimumabu (Bristol Myers Squibb). The drug is a human monoclonal antibody that blocks CTLA-4 antigen and the immune system to be active in the fight against melanoma cells.
 


In March 2011, FDA registered drug as monotherapy for the treatment of patients in stage III and IV disease. In July, ipilimumab was registered by the EMA. 
 


The three-arm randomized phase III trial randomized patients with unresectable melanoma of the III and stage IV, in which the disease had progressed after treatment system, compared ipilimumab glycopeptide vaccine (gp100). 
 


676 patients were randomized to three groups in a 3:1:1 ratio: ipilimumab (at a dose of 3 mg kg of body weight in cycles every 3 weeks for a total of four cycles) with the addition of gp100 vaccine (403 patients), ipilimumab alone at the same dose (137) and gp100 monotherapy (136).

Median survival in these groups were 10, 10.1 and 6.4 months. When it comes to overall survival, drug prolongs survival two of the patients compared to standard therapy. There is also fourth year survival. (Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, NEJM, 2010).

Immukoonkologia without targeted selection 

The genetically targeted therapies can be selected patients who respond to treatment - The treatment of isolated molecularly targeted group of patients in whom the target of the drug. For now, unfortunately there are no known predictors of treatment immunotherapy, work in progress - says prof. Rutkowski. 


On the basis of currently available clinical data treatment according to European ipilimumabem indications registration must first be considered in patients: 


  • Diagnosed with melanoma of the skin or mucous membranes in unresectable stage III or IV,
  • After previous unsuccessful treatment system (based on dacarbazine), up to 2 lines of therapy for systemic therapy or intolerance,
  • No metastasis to the brain or of asymptomatic brain metastases in good performance status (0/1 according to the criteria of ECOG - Eastern Cooperative Oncology Group, which allows the scale to determine the general condition and quality of life of patients with cancer).